Andrew Oh

Andrew Oh is the Chief Financial Officer at Rubius Therapeutics. Andrew has over fifteen years of experience in the financial industry, with a focus on the pharmaceutical sector.

Oh began their career as a Senior Partner at Flagship Pioneering. Andrew then served as a Senior Healthcare Analyst at Stifel Financial Corp. before moving to J.P. Morgan as a Senior Pharma Research Associate. In 2006, they joined Fidelity Investments as a Research Analyst and Portfolio Manager for the Fidelity Select Pharmaceuticals Fund. Andrew held this position for seven years before being promoted to Global Pharmaceuticals Analyst in 2013.

In 2014, Oh left Fidelity to co-found Leerink Pharmaceutical Investments LLC, where they served as Chief Investment Officer, Chief Operating Officer, and portfolio manager for the Leerink Pharmaceutical Fund. Andrew left Leerink in 2017 to join Rubius Therapeutics as Chief Financial Officer.

Andrew Oh has a Master of Business Administration (M.B.A.) from Northwestern University - Kellogg School of Management with a focus in management and strategy, finance, and marketing. Andrew also has a Bachelor of Arts (B.A.) in biology from Washington University in St. Louis and attended the Illinois Math and Science Academy.

Andrew Oh reports to Torben Straight Nissen, President. Some of their coworkers include Chris Carpenter - Chief Medical Officer, Tom Wickham - Vice President, Research and Development, and Avak Kahvejian - Co-Founder and Chief Innovation Officer.